AN ORDINANCE 96594

AUTHORIZING THE ACCEPTANCE OF AN AMOUNT NOT TO **EXCEED** \$800.00 IN **CASH FROM** GLAXOSMITHKLINE PHARMACEUTICALS BY THE SAN ANTONIO METROPOLITAN HEALTH DISTRICT TO PARTICIPATE IN A HAVRIX® VACCINE STUDY FOR THE PREVENTION OF HEPATITIS A IN CHILDREN FROM AUGUST 15, 2002 THROUGH NOVEMBER 21, 2002; AUTHORIZING THE **EXECUTION OF** AGREEMENT; ESTABLISHING THE PROJECT FUND; **ADOPTING** THE **PROGRAM BUDGET:** AND AUTHORIZING **PAYMENTS** FOR CONTRACTUAL SERVICES.

WHEREAS, the San Antonio Metropolitan Health District (SAMHD) operates a program that provides immunizations to children for the prevention of diseases such as measles, rubella, mumps, diphtheria, tetanus, polio, haemophilus influenza b, pertussis, hepatitis A and varicella; and

WHEREAS, the success of this effort is dependent on administering the proper vaccines to prevent disease outbreaks in the community; and

WHEREAS, GlaxoSmithKline Pharmaceuticals, a manufacturer of various medications, has developed HAVRIX®, a vaccine to prevent hepatitis A; and

WHEREAS, GlaxoSmithKline Pharmaceuticals has offered an agreement for an amount not to exceed \$800.00 in order for the SAMHD to participate in a clinical research study to evaluate the effectiveness of this vaccine and to determine the immune responses following co-administration of other routine childhood vaccines in young children for the period August 15, 2002 through November 21, 2002; and

WHEREAS, the City wishes to participate in this effort which promotes the expanded use of an FDA approved drug known to prevent hepatitis A; and

WHEREAS, it is now necessary to authorize the acceptance and execution of this agreement with GlaxoSmithKline Pharmaceuticals, establish a fund, adopt the project budget and authorize payments for contractual services; NOW THEREFORE:

BE IT ORDAINED BY THE CITY COUNCIL OF THE CITY OF SAN ANTONIO:

SECTION 1. The City Manager, or her designee, is hereby authorized to accept and execute an Investigator Agreement with GlaxoSmithKline Pharmaceuticals, which will provide an amount not to exceed \$800.00 in order for the San Antonio Metropolitan Health District to participate in a vaccine study for the prevention of hepatitis A in children during the period August 15, 2002 through November 21, 2002. A copy of this agreement is set out as Attachment II and incorporated herein for all purposes.

SECTION 2. Fund 26-012227 entitled "GlaxoSmithKline Havrix® 229 Vaccine Study Project" is designated for use in accounting for this project.

SECTION 3. The sum of \$800.00 is hereby appropriated in the above-designated fund for the GlaxoSmithKline Havrix® 229 Vaccine Study Project, and the budget attached hereto and incorporated herein as Attachment I is approved and adopted for entry on the City books.

SECTION 4. The Director of Finance, may, subject to concurrence by the City Manager or the City Manager's designee, correct allocation to specific index codes and fund numbers as necessary to carry out the purpose of this ordinance.

SECTION 5. Should the agreement offered be in an amount other than that budgeted for, or should the agreement contain terms and conditions different than those currently existing, acceptance of the agreement, budget and corresponding personnel complement will be subject to subsequent City Council ordinance.

SECTION 6. This ordinance shall be effective on and after the tenth day after passage hereof.

PASSED AND APPROVED this 24th day of October, 2002.

APPROVED AS TO FORM:

City Attorney

EDWARD D. GARZA